CURE’s myelodysplastic syndrome (MDS) page is an extensive resource of cancer information featuring the latest myelodysplastic syndrome news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on MDS.
September 24th 2024
An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.
September 19th 2024
Helping Others to Help Yourself Live Longer
August 31st 2018After we have been diagnosed with cancer, our lives will never be the same again. But we need to try to just perform one little service – a phone call, a card, an email to encourage others. The wonderful thing is with or without cancer, we may just live a little bit longer with joy!
Sometimes, Taking Care of Yourself Is Enough After Cancer
August 21st 2018Wistfully, I recall the days I could work all day, come home and do things around the house and then go out for dinner! Those days are long gone. I am off the chemo this week, but next week I will feel even more fatigue when I go back on.
Relatives of Patients With Myeloid Blood Cancers May be at Two-Fold Risk for Disease
August 14th 2018Recent research showed first-degree relatives of patients with certain types of blood cancers may be at an increased risk for such disease, highlighting the importance of counseling, gene testing and surveillance.
I'll Never Get to Ring the Bell
April 14th 2018Patients with cancer are often asked when they’ll be done with chemotherapy or treatment. Those of us with blood cancers and bone marrow type of cancers such as aplastic anemia, myelodysplastic syndrome, lymphoma and leukemia, along with a host of other cancers sadly have to say, “never.”
Elderly Patients Significantly Underrepresented in Hematology Clinical Trials
December 12th 2017Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.
Prevymis Approved to Prevent Virus in Patients Receiving Stem Cell Transplants
November 9th 2017Prevyis (letermovir) was granted approval by the Food and Drug Administration (FDA) to prevent cytomegalovirus (CMV) infection in adult CMV-seropositive patients treated with an allogeneic hematopoietic stem cell transplant (HSCT). The result is based on a significant reduction in CMV infection rates in a phase 3 study.